Liminatus Pharma Inc. is a clinical-stage biopharmaceutical company specializing in immuno-oncology therapies for cancer treatment. Established in 2018 and headquartered in La Palma, California, the company's primary focus is on developing innovative, immune-modulating cancer therapies that address unmet needs within oncology. Liminatus Pharma operates in the biotechnology sector, contributing to the advancement of new medical solutions by leveraging cutting-edge research in immune system-based approaches to combat cancer. Its clinical-stage pipeline and research initiatives place it at the forefront of developing targeted treatments aimed at improving patient outcomes and expanding available options for cancer care. In April 2025, the company achieved a notable milestone by completing a business combination with Iris Acquisition Corp., further solidifying its position and providing access to broader capital markets. Liminatus Pharma Inc. plays a significant role in the healthcare industry by pursuing novel solutions in cancer therapeutics, with a commitment to advancing the field of immuno-oncology.